Videos

2 experts in this video

Panelists discuss how shortened hormone-free intervals (24-4 and 24-2-2 regimens) prevent ovarian reactivation and endometrial proliferation that caused breakthrough bleeding with traditional 21/7 formulations, while addressing how amenorrhea can be viewed as either a desired therapeutic outcome or concerning adverse effect depending on patient preferences.

4 experts in this video

Panelists discuss how new FDA-approved treatments like zuranolone offer rapid onset options for postpartum depression, while monitoring effectiveness requires regular follow-up, rescreening, symptom assessment, and addressing global factors like sleep support and breastfeeding pressures.

4 experts in this video

Panelists discuss how treatment barriers include limited prescriptive access and long wait times, while successful treatment plans require assessing severity levels, maternal functioning, support systems, and incorporating follow-up care with appropriate interventions based on the patient’s specific needs.

4 experts in this video

Panelists discuss how to manage positive screens through resources like Postpartum Support International, state psychiatric consultation lines, combination therapy approaches, and addressing patient concerns about medication through evidence-based conversations and gradual implementation.